iVIEW Therapeutics成功完成Pre-IND会议, FDA全面认可IVW-1001针对干眼症临床前和临床开发计划
[2023/02/01] January 30, 2023 Cranbury, New Jersey iVIEW Therapeutics Inc., a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics, today announced that the company completed a successful pre-IND meeting with FDA and received the agency’s full agreement on all CMC, non-clinical and clinical development plans to develop IVW-1001 for the treatment of sign and symp……[获取详情]